Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer

Correction to: BTLA⁺CD200⁺ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer

Oncogene. 2023 Feb;42(8):625. doi: 10.1038/s41388-023-02606-9.

¹ S.A. Localio Laboratory, Departments of Surgery, New York University School of Medicine, New York, NY, USA.
² Department of Medicine, New York University School of Medicine, New York, NY, USA.
³ S.A. Localio Laboratory, Departments of Surgery, New York University School of Medicine, New York, NY, USA. gedalyamil@gmail.com.
⁴ Department of Cell Biology, New York University School of Medicine, New York, NY, USA. gedalyamil@gmail.com.
⁵ Trinity Health of New England, Waterbury, CT, USA. gedalyamil@gmail.com.

No abstract available